About 30 results found for searched term "Checkpoint" (0.226 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M1665 | AZD7762 | Checkpoint |
| AZD7762 is a potent ATP-competitive checkpoint kinase inhibitor with an IC50 of 5 and <10 nM for CHK1 and CHK2 respectively. | ||
| M1764 | PF-477736 | Checkpoint |
| PF-0044736 | ||
| PF-477736 is a selective checkpoint kinase 1 (Chk1) inhibitor with Ki values of 0.49 nM and 47 nM for CHK1 and CHK2 respectively. | ||
| M3686 | AZD7762 hydrochloride | Checkpoint |
| AZD-7762 HCl | ||
| AZD7762 hydrochloride is a potent ATP-competitive checkpoint kinase inhibitor with an IC50 of 5 and <10 nM for CHK1 and CHK2 respectively. | ||
| M5156 | CCT241533 hydrochloride | Checkpoint |
| CCT241533 HCl | ||
| CCT241533 hydrochloride is a potent serine/threonine checkpoint kinase (Chk2) inhibitor with IC50 of 3 nM. | ||
| M5648 | Floxuridine | DNA/RNA Synthesis |
| Deoxyfluorouridine; FDUR; NSC 27640 | ||
| Floxuridine (5-fluorouracil 2'-deoxyriboside) is a pyrimidine analogue that is also an antitumor metabolite of oncology. Floxuridine inhibits the Poly(ADP-Ribose) polymerase and induces DNA damage in vitro by activating ATM and ATR checkpoint signaling pathways. Floxuridine is an effective inhibitor of Staphylococcus aureus infection and can induce apoptosis. Floxuridine is resistant to HSV and CMV viruses. | ||
| M6100 | Nivolumab | PD-1/PD-L1 |
| BMS-936558, ONO-4538, MDX-1106；Opdivo | ||
| Nivolumab (nabumab) is a fully humanized IgG4 monoclonal antibody against PD-1. It has immune checkpoint inhibitory activity and antitumor activity; MW: 143.597 KD.(for human-derived mice). | ||
| M6102 | Pembrolizumab | PD-1/PD-L1 |
| Lambrolizumab; MK-3475；Keytruda | ||
| Pembrolizumab (pembrolizumab) is a humanized anti-PD-1 monoclonal antibody that blocks the interaction between PD-1 and its ligands PD-L1 and PD-L2. It has immune checkpoint inhibitory activity and antitumor activity. MW: 146.286 KD.(Pembrolizumab does not recognize murine PD-1 protein, humanized mice or mice expressing human PD-1 gene are required). | ||
| M6104 | Ipilimumab | Checkpoint |
| MDX-010, BMS-734016；Yervoy | ||
| Ipilimumab (MDX-010, BMS-734016) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor. MW : 148 kD. | ||
| M7255 | SB 218078 | Others |
| SB 218078 is a inhibitor of checkpoint kinase 1 (Chk1). | ||
| M7986 | OM137 | Others |
| OM137 is an inhibitor of aurora kinases; inhibitor of spindle checkpoint. | ||
| M9897 | GB1107 | Galectin |
| GB-1107 | ||
| GB1107 is a potent, selective, orally active galectin-3 inhibitor with Kd of 37 nM. GB1107 inhibits lung adenocarcinoma growth and augments response to PD-L1 blockade. GB1107 potentiates the effects of a PD-L1 immune checkpoint inhibitor to increase expression of cytotoxic (IFN-γ, granzyme B, perforin-1, Fas ligand) and apoptotic (cleaved caspase-3) effector molecules. | ||
| M10129 | CCT245737 | Checkpoint |
| SRA737; PNT-737 | ||
| CCT245737 is a potent, selective and orally active checkpoint kinase 1 (CHK1) inhibitor, with IC50 values of 1.3 nM, 2440 nM and 30 nM for CHK1, CHK2 and G2 check point abrogation, respectively. | ||
| M10130 | AZD0156 | ATM/ATR |
| AZD-0156 | ||
| AZD0156 is a potent, selective and orally active ATM inhibitor with an IC50 of 0.58 nM. AZD0156 inhibits ATM mediated signal transduction, prevents DNA damage checkpoint activation, damages DNA damage repair, and induces tumor cell apoptosis. | ||
| M10288 | BMS-1001 | PD-1/PD-L1 |
| BMS-1001 free base; BMS1001 | ||
| Bms-1001 Hydrochloride is orally active and is an inhibitor of the human PD-L1/PD-1 immune checkpoint. Bms-1001 Hydrochloride is characterized by low cytotoxicity.r. | ||
| M10476 | GDC-0575 (ARRY-575) | Checkpoint |
| RG7741; ARRY575; AK-687476 | ||
| GDC-0575 (ARRY-575, RG7741) is a potent and selective oral inhibitor of cell cycle checkpoint kinase 1 (Chk1) with an IC50 of 1.2 nM. | ||
| M10583 | RRX-001 | NLR |
| ABDNAZ | ||
| Rrx-001 is a hypoxic selective epigenetic factor that has been used as a radiation or chemotherapy sensitizer to induce apoptosis. Rrx-001 is an immune checkpoint inhibitor that down-regulates CD47 and SIRP-α. Rrx-001 is also an effective inhibitor of G6PD with strong antimalarial activity. Rrx-001 inhibits the expression of CD47 in tumor cells by inhibiting c-myC, a positive regulator of CD47. | ||
| M10852 | M-4344 | Others |
| VX-803 (M4344, ATR inhibitor 2) is a selective inhibitor of ATAxia telangiectasia and Rad3 related (ATR) kinase with a Ki value of less than 150 pM. VX-803 (M4344) effectively inhibits ATR-driven phosphorylated checkpoint kinase-1 (P-Chk1) phosphorylation with an IC50 value of 8 nM. VX-803 (M4344) has potential antitumor activity. | ||
| M11251 | Gartisertib | ATM/ATR |
| VX-803; M4344; ATR inhibitor 2 | ||
| Gartisertib (VX-803) is an ATP-competitive, orally active, selective ATR inhibitor with Ki<150 pM. Gartisertib inhibits atR-driven phosphorylation of checkpoint kinase-1 (Chk1) with an IC50 value of 8 nM. It has antitumor activity. | ||
| M13620 | CCT244747 | Checkpoint |
| CCT244747 is a potent, orally bioavailable and highly selective CHK1 inhibitor, with an IC50 of 7.7 nM; CCT244747 also abrogates G2 checkpoint with an IC50 of 29 nM. | ||
| M13622 | Prexasertib | Checkpoint |
| LY2606368 | ||
| Prexasertib (LY2606368) is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a Ki of 0.9 nM and an IC50 of <1 nM. | ||
| M13623 | Prexasertib dimesylate | Checkpoint |
| LY2606368 dimesylate | ||
| Prexasertib dimesylate (LY2606368 dimesylate) is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a Ki of 0.9 nM and an IC50 of <1 nM. | ||
| M20859 | AUNP-12 | PD-1/PD-L1 |
| Aur-012, Aurigene-012, Aurigene NP-12 | ||
| AUNP-12, a new immune checkpoint modulator, is an inhibitor of the PD-1 pathway. | ||
| M21002 | BOS172722 | Others |
| BOS172722 is a monopolar spindle 1 (MPS1) checkpoint inhibitor with IC50 of 11 nM, Ki of 0.11 nM. | ||
| M21501 | Monalizumab | Checkpoint |
| IPH2201 | ||
| Monalizumab is a first-in-class immune checkpoint inhibitor targeting natural killer cell population 2A (NKG2A). Monalizumab can be used in the study of head and neck squamous cell carcinoma (HNSCC). | ||
| M24851 | Tiragolumab | TIGIT |
| Tiragolumab is an immune checkpoint inhibitor that binds to T-cell immunoglobulin and the structural domain of ITIM (TIGIT), targets TIGIT and has an intact Fc region. Tiragolumab is indicated for use in studies related to solid tumors. | ||
| M24930 | Fianlimab | Others |
| REGN3767 | ||
| Fianlimab (REGN3767) is a human monoclonal antibody that targets the immune checkpoint receptor LAG-3 on T cells and has anti-tumour activity. | ||
| M24934 | Ontorpacept | Others |
| TTI-621 | ||
| Ontorpacept (TTI-621) is a soluble fusion protein that consists of the human SIRPα N-terminal (1-118) linked to the Fc region of human IgG1. The N-terminal (1-118)-fragment of ontorpacept is a binding domain for CD47 which is an inhibitor of phagocytosis by macrophages. Ontorpacept is a CD47-blocking checkpoint inhibitor with antitumor activity. | ||
| M24952 | Zalifrelimab | Others |
| AGEN1884 | ||
| Zalifrelimab (AGEN1884) is a fully human IgG1 monoclonal antibody targeting CTLA-4 (CTLA-4). Zalifrelimab antagonizes the inhibitory checkpoints of immune cell activation regulated by CTLA-4 signaling. | ||
| M24960 | Neihulizumab | Apoptosis |
| ALTB-168; Anti-PSGL1/CD162 Reference Antibody | ||
| Neihulizumab (ALTB-168) is an immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), leading to downregulation of activated T-cells. Neihulizumab can be uesd for steroid-refractory acute graft-versus-host-disease (SR-aGVHD), psoriasis, psoriatic arthritis and ulcerative colitis research. | ||
| M25004 | Tinurilimab | Others |
| BAY 1834942 | ||
| Tinurilimab (Bay 1834942) is an anti-CEACAM6 monoclonal antibody. CEACAM6 is an immune checkpoint regulator suppressing the activity of effector T-cells against tumors. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
